In several previous studies including our own, decreased e-cadherin expression either alone or in combination with other biomarkers has been described as being associated with prostate cancer progression (Umbas et al, 1992; Takeichi, 1993; Rubin et al, 2001; Rhodes et al, 2003). Here, CDH1 is linked to prostate carcinoma.